TitleSequential transcription factor targeting for diffuse large B-cell lymphomas.
Publication TypeJournal Article
Year of Publication2008
AuthorsCerchietti, Leandro C., Polo Jose M., Da Silva Gustavo F., Farinha Pedro, Shaknovich Rita, Gascoyne Randy D., Dowdy Steven F., and Melnick Ari
JournalCancer Res
Date Published2008 May 01
KeywordsAmino Acid Sequence, Antineoplastic Agents, Cell Death, Cell Line, Tumor, DNA-Binding Proteins, Drug Delivery Systems, Drug Synergism, Gene Expression Regulation, Neoplastic, Humans, Lymphoma, Large B-Cell, Diffuse, Molecular Sequence Data, Peptide Fragments, Peptides, Proto-Oncogene Proteins c-bcl-6, Signal Transduction, Transcription Factors, Tumor Suppressor Protein p53, Up-Regulation

<p>Transcription factors play a central role in malignant transformation by activating or repressing waves of downstream target genes. Therapeutic targeting of transcription factors can reprogram cancer cells to lose their advantages in growth and survival. The BCL6 transcriptional repressor plays a central role in the pathogenesis of diffuse large B-cell lymphomas (DLBCL) and controls downstream checkpoints, including the p53 tumor suppressor gene. We report that a specific inhibitor of BCL6 called BPI can trigger a p53 response in DLBCL cells. This was partially due to induction of p53 activity and partially due to relief of direct repression by BCL6 of p53 target genes. BPI could thus induce a p53-like response even in the presence of mutant p53. Moreover, sequential BCL6 peptide inhibitors followed by p53 peptide or small-molecule activators provided a more powerful antilymphoma effect than either treatment alone by maximally restoring p53 target gene expression. Therefore, tandem targeting of the overlapping BCL6 and p53 transcriptional programs can correct aberrant survival pathways in DLBCL and might provide an effective therapeutic approach to lymphoma therapy.</p>

Alternate JournalCancer Res
PubMed ID18451163
PubMed Central IDPMC2748725
Grant ListR01 CA104348 / CA / NCI NIH HHS / United States
R01 CA104348-05 / CA / NCI NIH HHS / United States